« Return to News | Drug Sponsors

Sysmex acquires Inostics

Wednesday, September 25, 2013 12:29 PM

Privately-held biotech company Indivumed, based in Hamburg, Germany, has announced that Inostics and its Baltimore-based subsidiary have been sold to Sysmex, a developer and manufacturer of instruments, reagents and software needed for in-vitro diagnostics, headquartered in Japan.

Inostics possesses advanced genetic testing technologies, such as ultra-sensitive digital PCR technology for detecting cancer cell DNA directly from blood—a "liquid biopsy" process as opposed to tissue testing. Sysmex plans to develop on a global basis assay services that Inostics already provides. Sysmex's companion diagnostics activities, in collaboration with pharmaceutical companies, will also be enhanced.

In 2008, following a five-year collaboration with Dr. Bert Vogelstein and his team at Johns Hopkins University in Baltimore, Indivumed and these scientists founded Inostics to commercialize the "BEAMing-Technology."

"With Sysmex, we expect achieving our goal to make Inostics technology the leading approach for DNA-based cancer diagnostics for the worldwide benefit of cancer patients.

The fact that Sysmex has its European headquarter in the Hamburg area facilitates a smooth transition and an undelayed continuation of Inostics business," said Dr. Frank Diehl, co-founder of Inostics, who continues to work for Inostics as chief scientific officer and managing director.

Indivumed will independently expand its tissue-based clinical research service business leveraging a comprehensive tumor-biobank and its prowess in the analysis of proteins and cancer pathways for drug development and patient diagnostics.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.